74
Artificial intelligence-driven drug developer Pathos AI has partnered with pharmaceutical company Bristol Myers Squibb and healthcare technology
firm Tempus AI to advance research into Alzheimer’s disease and other neurological conditions. The collaboration will combine AI-powered drug
development tools with large-scale patient data.
Announced on October 23, the collaboration coincided with Pathos AI closing a $237 million Series E funding round led by Bristol Myers Squibb, valuing the company at approximately $3 billion. Existing investors also participated in the round.
Under a five-year agreement worth up to $55 million, Tempus AI will provide Pathos with 500,000 de-identified patient records covering Alzheimer’s disease and other specified neurological conditions. The dataset is intended to help researchers study disease progression, identify biological patterns and improve their understanding of potential treatment opportunities.
Pathos will analyse the data using Foundry, its proprietary AI-powered drug development platform. The system is designed to examine clinical and genomic information, generate and test hypotheses about disease biology, and support decisions on drug development and clinical-trial design. Bristol Myers Squibb will contribute its neuroscience research and drug development expertise. The pharmaceutical company will gain non- exclusive strategic access to Foundry across its broader research and development portfolio, alongside three-year exclusive rights to use the platform in its neuroscience development programmes.
The collaboration expands Pathos AI’s work beyond oncology into neurological research, where developing effective treatments remains challenging. Alzheimer’s disease is a progressive neurological condition, and researchers continue to investigate its underlying biology and seek therapies that can improve patient outcomes.
The agreement reflects growing interest in applying artificial intelligence to pharmaceutical research. By analysing large datasets, AI tools may help researchers identify patterns, refine hypotheses and select patient groups for clinical studies. However, these findings require scientific validation, and AI-generated insights alone cannot establish that a drug candidate is safe or effective.
Pathos said the Series E proceeds will also support the expansion of its Foundry platform and advance its existing drug development pipeline, including experimental cancer therapies. The funding therefore supports the company’s broader development strategy, while the collaboration with Tempus AI and Bristol Myers Squibb specifically targets Alzheimer’s disease and other neurological conditions.
The partnership does not represent the discovery or approval of a new Alzheimer’s treatment. Any potential therapies emerging from the research would need to undergo clinical testing and regulatory review. The collaboration’s impact will ultimately depend on whether the combined data, AI capabilities and pharmaceutical expertise can produce validated scientific insights and translate them into effective treatments.
Announced on October 23, the collaboration coincided with Pathos AI closing a $237 million Series E funding round led by Bristol Myers Squibb, valuing the company at approximately $3 billion. Existing investors also participated in the round.
Under a five-year agreement worth up to $55 million, Tempus AI will provide Pathos with 500,000 de-identified patient records covering Alzheimer’s disease and other specified neurological conditions. The dataset is intended to help researchers study disease progression, identify biological patterns and improve their understanding of potential treatment opportunities.
Pathos will analyse the data using Foundry, its proprietary AI-powered drug development platform. The system is designed to examine clinical and genomic information, generate and test hypotheses about disease biology, and support decisions on drug development and clinical-trial design. Bristol Myers Squibb will contribute its neuroscience research and drug development expertise. The pharmaceutical company will gain non- exclusive strategic access to Foundry across its broader research and development portfolio, alongside three-year exclusive rights to use the platform in its neuroscience development programmes.
The collaboration expands Pathos AI’s work beyond oncology into neurological research, where developing effective treatments remains challenging. Alzheimer’s disease is a progressive neurological condition, and researchers continue to investigate its underlying biology and seek therapies that can improve patient outcomes.
The agreement reflects growing interest in applying artificial intelligence to pharmaceutical research. By analysing large datasets, AI tools may help researchers identify patterns, refine hypotheses and select patient groups for clinical studies. However, these findings require scientific validation, and AI-generated insights alone cannot establish that a drug candidate is safe or effective.
Pathos said the Series E proceeds will also support the expansion of its Foundry platform and advance its existing drug development pipeline, including experimental cancer therapies. The funding therefore supports the company’s broader development strategy, while the collaboration with Tempus AI and Bristol Myers Squibb specifically targets Alzheimer’s disease and other neurological conditions.
The partnership does not represent the discovery or approval of a new Alzheimer’s treatment. Any potential therapies emerging from the research would need to undergo clinical testing and regulatory review. The collaboration’s impact will ultimately depend on whether the combined data, AI capabilities and pharmaceutical expertise can produce validated scientific insights and translate them into effective treatments.
